Current era outcomes of pulmonary atresia with ventricular septal defect: A single center cohort between 2005 and 2016
Not Applicable
Completed
- Conditions
- -Pulmonary atresia with ventriculsr septal defect is a complex congenital heart disease which has various clinical manifestation owing to individual central pulmonary artery anatomy and pulmonary discongenital heart diseasepulmonary atresia with ventricular septal defectSurvival rateprognosis
- Registration Number
- TCTR20190118013
- Lead Sponsor
- Division of Pediatric cardiology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
all incident pediatric patients who were diagnosed with PA/VSD by echocardiography between January 1, 2005 and December 31, 2016 in Siriraj Hospital, Mahidol University
Exclusion Criteria
Patients with single ventricle or had undergone cardiac operation from other hospital were excluded.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival November 2018 Mortality
- Secondary Outcome Measures
Name Time Method Mortiality risks November 2018 Risk analysis
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms influence survival rates in pulmonary atresia with ventricular septal defect patients?
How does the current trial's outcome data compare to standard-of-care treatments for complex congenital heart disease?
Are there specific biomarkers that correlate with prognosis in pulmonary atresia with ventricular septal defect subtypes?
What adverse events are commonly associated with pulmonary artery interventions in congenital heart disease?
How do pulmonary artery anatomies affect therapeutic strategies in congenital heart defects like TCTR20190118013?